文献速递骨质疏松与代谢性骨病创伤骨科

二甲双胍使用与骨折风险:观察性研究的系统综述与荟萃分析

Metformin use and risk of fracture: a systematic review and meta-analysis of observational studies.
PubMed 文献 · Osteoporos Int · 2019-03-29

该系统综述与荟萃分析检索截至2018年10月的观察性研究,纳入6项研究(3项队列、1项横断面、1项巢式病例对照、1项病例对照),合并7个效应量后发现二甲双胍使用与骨折风险呈显著负相关(RR 0.82;95% CI 0.72, 0.93),研究间异质性无统计学意义(I²=22.4%,Pheterogeneity=0.25),Egger检验未见发表偏倚证据(P=0.99)。

要点

  • 二甲双胍使用与骨折风险呈显著负相关(RR 0.82;95% CI 0.72, 0.93)。
  • 合并6项观察性研究的7个效应量,研究间异质性无统计学意义(I²=22.4%,Pheterogeneity=0.25)。
  • Egger检验未见发表偏倚证据(P=0.99)。

核心结论

  • 二甲双胍使用与骨折风险呈负相关。

研究设计与样本

  • 系统检索PubMed/Medline、ISI Web of Science和Scopus截至2018年10月的已发表文章。
  • 纳入以二甲双胍使用为暴露变量、骨折为主要或结局变量之一、参与者年龄18岁及以上的观察性研究。
  • 共纳入6项研究:3项队列研究、1项横断面研究、1项巢式病例对照研究和1项病例对照研究。
  • 报告风险比(HR)、率比或风险比(RR)、比值比(OR)作为效应量的出版物被纳入荟萃分析。

主要发现

  • 合并6项研究的7个效应量,二甲双胍使用与骨折风险呈显著负相关(RR 0.82;95% CI 0.72, 0.93)。
  • 研究间异质性无统计学意义(I²=22.4%,Pheterogeneity=0.25)。
  • Egger检验未见发表偏倚证据(P=0.99)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: No study is available summarizing earlier publications on the association between metformin use and risk of fracture. This systematic review and meta-analysis were conducted to summarize earlier findings on the association between metformin use and risk of fracture. METHODS: We conducted a systematic search on all published articles up to October 2018 using online databases including PubMed/Medline, ISI Web of Science, and Scopus. Observational studies that considered metformin use as the exposure variable and bone fracture as the main outcome variable or as one of the outcome variables and participants included were 18 years and older were included in the systematic review. Publications in which hazard ratios (HRs), rate or risk ratios (RRs), or odds ratios (ORs) were reported as effect size were included in the meta-analysis. RESULTS: Totally, three cohort studies, one cross-sectional study, one nested case-control study, and one case-control study were included in this systematic review and meta-analysis. When seven effect sizes from six studies were combined, a significant inverse association between metformin use and risk of fracture was observed (RR 0.82; 95% CI 0.72, 0.93). No significant between-study heterogeneity was found (I2 = 22.4%, Pheterogeneity = 0.25). In addition, no evidence of publication bias was seen using Egger's test (P = 0.99). CONCLUSION: We found that metformin use was inversely associated with the risk of fracture.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Salari-Moghaddam A, Sadeghi O, Keshteli AH, et al. Metformin use and risk of fracture: a systematic review and meta-analysis of observational studies. Osteoporos Int. 2019. PMID: 30927035. doi:10.1007/s00198-019-04948-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。